Global Anti-ANGPTL3 Antibody Supply, Demand and Key Producers, 2026-2032
The global Anti-ANGPTL3 Antibody market size is expected to reach $ 313 million by 2032, rising at a market growth of 9.5% CAGR during the forecast period (2026-2032).
In 2025, global Anti-ANGPTL3 Antibody production reached approximately 18.88 K Boxes, with an average global market price of around 8121 USD per Box.
An anti-ANGPTL3 antibody is a monoclonal antibody designed to bind and inhibit angiopoietin-like protein 3 (ANGPTL3), a circulating liver-derived protein that regulates lipid metabolism by suppressing lipoprotein lipase (and related pathways). By neutralizing ANGPTL3’s activity, these antibodies aim to increase triglyceride-rich lipoprotein clearance and reduce atherogenic lipids (such as LDL cholesterol and triglycerides), and are used or developed for treating severe dyslipidemias and reducing cardiovascular risk.Evolocumab is the only marketed anti-ANGPTL3 antibody globally. It has been approved by the US FDA for the treatment of homozygous familial hypercholesterolemia (HoFH).
Anti-ANGPTL3 antibodies are compelling because they target a well-defined, liver-driven control point in lipid metabolism that can address a persistent industry pain point: a subset of patients remain at high cardiovascular risk despite today’s standard lipid-lowering options, either because of severe inherited dyslipidemias, mixed lipid abnormalities, intolerance, or residual risk that is not fully captured by LDL-centric approaches. By neutralizing ANGPTL3, these antibodies can reduce atherogenic lipoprotein burden through mechanisms that are complementary to statins and PCSK9 inhibitors, offering clinicians a differentiated tool when conventional pathways plateau and enabling a precision-medicine narrative for complex lipid phenotypes where triglycerides, remnants, and broader dyslipidemia matter. The category is being propelled by structural drivers that have reshaped cardiometabolic drug development: rising global prevalence of obesity and diabetes, stronger emphasis on preventing costly downstream events, increasing sophistication in genetic and biomarker-enabled patient identification, and growing confidence among payers and health systems in high-value biologics that demonstrate meaningful risk reduction in well-defined populations. Anti-ANGPTL3 antibodies have credible market runway as evidence and clinical experience mature, positioning expands from rare and refractory patients toward broader high-risk segments where unmet need remains, and combination strategies with established lipid therapies become more clearly standardized, making the class an attractive long-term opportunity within the evolving cardiometabolic landscape without relying on exaggerated claims.
The upstream raw materials for anti-ANGPTL3 antibody mainly include ANGPTL3 recombinant protein, CHO cells, etc. Typical raw material suppliers include Thermo Fisher, Merck, Pall, etc. The downstream application is mainly for people with high blood lipids.
The production capacity of anti-ANGPTL3 antibody production lines varies greatly depending on the type of drug molecule, process complexity, equipment scale, and production mode. The industry gross profit margin is usually in the range of 60%-80%.
This report studies the global Anti-ANGPTL3 Antibody production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-ANGPTL3 Antibody and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-ANGPTL3 Antibody that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Anti-ANGPTL3 Antibody total production and demand, 2021-2032, (K Boxes)
Global Anti-ANGPTL3 Antibody total production value, 2021-2032, (USD Million)
Global Anti-ANGPTL3 Antibody production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Boxes), (based on production site)
Global Anti-ANGPTL3 Antibody consumption by region & country, CAGR, 2021-2032 & (K Boxes)
U.S. VS China: Anti-ANGPTL3 Antibody domestic production, consumption, key domestic manufacturers and share
Global Anti-ANGPTL3 Antibody production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Boxes)
Global Anti-ANGPTL3 Antibody production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Boxes)
Global Anti-ANGPTL3 Antibody production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Boxes)
This report profiles key players in the global Anti-ANGPTL3 Antibody market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Regeneron, Eli Lilly, Jiangsu Hengrui Medicine, Cspc Holdings, Suzhou Ribo Life Science, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-ANGPTL3 Antibody market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Boxes) and average price (USD/Box) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Anti-ANGPTL3 Antibody Market, By Region:
1. How big is the global Anti-ANGPTL3 Antibody market?
2. What is the demand of the global Anti-ANGPTL3 Antibody market?
3. What is the year over year growth of the global Anti-ANGPTL3 Antibody market?
4. What is the production and production value of the global Anti-ANGPTL3 Antibody market?
5. Who are the key producers in the global Anti-ANGPTL3 Antibody market?
6. What are the growth factors driving the market demand?
In 2025, global Anti-ANGPTL3 Antibody production reached approximately 18.88 K Boxes, with an average global market price of around 8121 USD per Box.
An anti-ANGPTL3 antibody is a monoclonal antibody designed to bind and inhibit angiopoietin-like protein 3 (ANGPTL3), a circulating liver-derived protein that regulates lipid metabolism by suppressing lipoprotein lipase (and related pathways). By neutralizing ANGPTL3’s activity, these antibodies aim to increase triglyceride-rich lipoprotein clearance and reduce atherogenic lipids (such as LDL cholesterol and triglycerides), and are used or developed for treating severe dyslipidemias and reducing cardiovascular risk.Evolocumab is the only marketed anti-ANGPTL3 antibody globally. It has been approved by the US FDA for the treatment of homozygous familial hypercholesterolemia (HoFH).
Anti-ANGPTL3 antibodies are compelling because they target a well-defined, liver-driven control point in lipid metabolism that can address a persistent industry pain point: a subset of patients remain at high cardiovascular risk despite today’s standard lipid-lowering options, either because of severe inherited dyslipidemias, mixed lipid abnormalities, intolerance, or residual risk that is not fully captured by LDL-centric approaches. By neutralizing ANGPTL3, these antibodies can reduce atherogenic lipoprotein burden through mechanisms that are complementary to statins and PCSK9 inhibitors, offering clinicians a differentiated tool when conventional pathways plateau and enabling a precision-medicine narrative for complex lipid phenotypes where triglycerides, remnants, and broader dyslipidemia matter. The category is being propelled by structural drivers that have reshaped cardiometabolic drug development: rising global prevalence of obesity and diabetes, stronger emphasis on preventing costly downstream events, increasing sophistication in genetic and biomarker-enabled patient identification, and growing confidence among payers and health systems in high-value biologics that demonstrate meaningful risk reduction in well-defined populations. Anti-ANGPTL3 antibodies have credible market runway as evidence and clinical experience mature, positioning expands from rare and refractory patients toward broader high-risk segments where unmet need remains, and combination strategies with established lipid therapies become more clearly standardized, making the class an attractive long-term opportunity within the evolving cardiometabolic landscape without relying on exaggerated claims.
The upstream raw materials for anti-ANGPTL3 antibody mainly include ANGPTL3 recombinant protein, CHO cells, etc. Typical raw material suppliers include Thermo Fisher, Merck, Pall, etc. The downstream application is mainly for people with high blood lipids.
The production capacity of anti-ANGPTL3 antibody production lines varies greatly depending on the type of drug molecule, process complexity, equipment scale, and production mode. The industry gross profit margin is usually in the range of 60%-80%.
This report studies the global Anti-ANGPTL3 Antibody production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-ANGPTL3 Antibody and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-ANGPTL3 Antibody that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Anti-ANGPTL3 Antibody total production and demand, 2021-2032, (K Boxes)
Global Anti-ANGPTL3 Antibody total production value, 2021-2032, (USD Million)
Global Anti-ANGPTL3 Antibody production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Boxes), (based on production site)
Global Anti-ANGPTL3 Antibody consumption by region & country, CAGR, 2021-2032 & (K Boxes)
U.S. VS China: Anti-ANGPTL3 Antibody domestic production, consumption, key domestic manufacturers and share
Global Anti-ANGPTL3 Antibody production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Boxes)
Global Anti-ANGPTL3 Antibody production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Boxes)
Global Anti-ANGPTL3 Antibody production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Boxes)
This report profiles key players in the global Anti-ANGPTL3 Antibody market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Regeneron, Eli Lilly, Jiangsu Hengrui Medicine, Cspc Holdings, Suzhou Ribo Life Science, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-ANGPTL3 Antibody market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Boxes) and average price (USD/Box) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Anti-ANGPTL3 Antibody Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Direct Neutralization
- Indirect Inhibition
- Others
- Direct Neutralization
- Indirect Inhibition
- Others
- Intravenous Injection
- Subcutaneous Injection
- Homozygous Familial Hypercholesterolaemia (HoFH)
- Others
- Regeneron
- Eli Lilly
- Jiangsu Hengrui Medicine
- Cspc Holdings
- Suzhou Ribo Life Science
1. How big is the global Anti-ANGPTL3 Antibody market?
2. What is the demand of the global Anti-ANGPTL3 Antibody market?
3. What is the year over year growth of the global Anti-ANGPTL3 Antibody market?
4. What is the production and production value of the global Anti-ANGPTL3 Antibody market?
5. Who are the key producers in the global Anti-ANGPTL3 Antibody market?
6. What are the growth factors driving the market demand?
